Disc Medicine reported a net loss of $62.3 million for Q3 2025, an increase from $26.6 million in Q3 2024, primarily due to higher operating costs. The company submitted an NDA for bitopertin in EPP and received a National Priority Voucher, aiming for accelerated approval. Cash and cash equivalents stood at $615.9 million, with a recent public offering extending the cash runway into 2029.

Disc Medicine reported a net loss of $55.2 million for Q2 2025, an increase from $26.4 million in Q2 2024, primarily due to higher operating costs driven by the progression of its clinical pipeline. The company ended the quarter with a strong cash position of $650.0 million, expected to fund operations into 2028.

Disc Medicine reported a net loss of $34.1 million for Q1 2025, an increase from $26.9 million in Q1 2024, primarily due to higher operating costs. The company ended the quarter with $694.7 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028. Key operational milestones include the initiation of the APOLLO trial for bitopertin in EPP and progress in the DISC-0974 program.

Disc Medicine reported its Q4 and full year 2024 financial results, highlighting a strong financial position with $490 million in cash, cash equivalents, and marketable securities. The company is targeting an NDA submission for bitopertin in H2 2025 and anticipates initiating a Phase 2 study for DISC-3405 in H1 2025.

Disc Medicine reported a net loss of $26.6 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $487.4 million as of September 30, 2024. They also completed a $200 million non-dilutive debt financing in November 2024.

Disc Medicine reported its Q2 2024 financial results, highlighting positive data presentations at the EHA Congress for all three programs and a strengthened financial position with $501 million in cash, cash equivalents, and marketable securities. The company expects this to fund operations well into 2027. The company's net loss was $26.4 million for the quarter.

Disc Medicine reported a net loss of $26.9 million for the quarter ended March 31, 2024. The company's cash and cash equivalents totaled $342.6 million, expected to fund operations well into 2026.

Disc Medicine reported its Q4 and full year 2023 financial results, highlighting positive read-outs for bitopertin and DISC-0974 and advancement of DISC-3405 into the clinic. The company ended the year with approximately $360.4 million in cash and cash equivalents.

Disc Medicine reported its Q3 2023 financial results, highlighting the completion of enrollment for the BEACON and AURORA trials and the advancement of their third development program into the clinic. The company's cash position is strong, with $370.5 million in cash and cash equivalents, expected to fund operations well into 2026. Key data presentations are anticipated at the upcoming ASH 2023 meeting.

Disc Medicine reported a net loss of $15.9 million for the second quarter of 2023. The company's cash and cash equivalents were $377.6 million as of June 30, 2023, which are expected to fund operational plans well into 2026.

Disc Medicine reported its Q1 2023 financial results, highlighting ongoing clinical studies for bitopertin and DISC-0974, in-licensing of anti-TMPRSS6 monoclonal antibodies, and a completed $62.5 million financing. The company's cash and cash equivalents were $236.4 million as of March 31, 2023, expected to fund operations into 2025.

Disc Medicine reported its full year 2022 financial results, highlighting its transformation into a publicly-traded company through a reverse merger with Gemini Therapeutics. The company ended the year with $194.6 million in cash and cash equivalents and advanced its pipeline programs, including bitopertin and DISC-0974, into clinical studies.

Gemini Therapeutics reported its full year 2021 financial results, revealing a net loss of $71.9 million. The company is currently evaluating strategic options to maximize shareholder value.

Gemini Therapeutics reported a net loss of $18.6 million, or $0.43 per share, for the three months ended September 30, 2021. The company held $150.1 million in cash as of September 30, 2021.

Gemini Therapeutics reported a net loss of $16.4 million, or $0.38 per share, for the second quarter ended June 30, 2021. The company's research and development expenses totaled $10.8 million, and general and administrative expenses were $5.5 million. As of June 30, 2021, Gemini held $167.5 million in cash.